For the Inventor, By the Inventor

Enter assignee name

Fort Worth, TX, United States of America

Galderma Laboratories Inc.

Calculating rank

USPTO Granted Patents = 27

% Expired Patents = 48.1

EPO Patents = 2

Trademarks = 9

Forward Citations = 245

Loading Chart...

Loading Chart...

21 inventors (with patents filed for the assignee):

Jack A DeJovin (12 out of 12 patents)

Isabelle Jean DeJovin (10 out of 10 patents)

Robert A Ashley (7 out of 17 patents)

4. Michael Graeber (6 out of 30 patents)

5. Philip Freidenreich (6 out of 7 patents)

6. Matthew James Leoni (6 out of 10 patents)

7. Christian Loesche (6 out of 12 patents)

8. Yin-sang Liu (4 out of 4 patents)

9. Yin-Sang Liu (2 out of 2 patents)

10. Philippe Andres (1 out of 14 patents)

11. Jean-Christophe Buge (1 out of 11 patents)

12. André Jomard (1 out of 8 patents)

13. Arthur Clapp (1 out of 3 patents)

14. Christopher Powala (1 out of 9 patents)

15. Karine Nadau Fourcade (1 out of 2 patents)

Core Competencies:

Brimonidine

Acne Treatment

Erythema

Psoriasis

Inflammatory Skin Disorders

Combination Therapy

Facial Flushing

Telangiectasis

Skin Wrinkles

Rosacea

Thrombin Inhibition

27 patents: Sort by Forward Citations

1. 10201517 - Brimonidine gel compositions and methods of use (2019-02-12),

2. 10058564 - Methods of treating acne (2018-08-28),

3. 9861632 - Methods and compositions for safe and effective treatment of erythema (2018-01-09),

4. 9861631 - Methods and compositions for safe and effective treatment of erythema (2018-01-09),

5. 9744168 - Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors (2017-08-29),

6. 9241946 - Methods of treating acne (2016-01-26),

7. 9186358 - Combination therapy for treating or preventing an inflammatory skin disorder (2015-11-17),

8. 9072739 - Method for treating psoriasis (2015-07-07),

9. 8993571 - Compounds, formulations, and methods for treating or preventing inflammatory skin disorders (2015-03-31),

10. 8859551 - Compounds, formulations, and methods for treating or preventing inflammatory skin disorders (2014-10-14),

11. 8658189 - Methods of treating acne (2014-02-25),

12. 8603506 - Methods of treating acne (2013-12-10),

13. 8586586 - Methods and compositions for treating or preventing erythema (2013-11-19),

14. 8557817 - Compounds, formulations, and methods for treating or preventing inflammatory skin disorders (2013-10-15),

15. 8513249 - Methods and compositions for safe and effective treatment of erythema (2013-08-20),

Company Overview

Galderma Laboratories Inc. is a global leader in dermatology, dedicated to advancing skin health through innovative products and solutions. The company specializes in developing and manufacturing a wide range of medical and aesthetic dermatological treatments, including prescription medications, over-the-counter products, and cosmetic injectables. With a strong focus on research and development, Galderma aims to address various skin conditions and enhance the quality of life for patients worldwide, operating from its headquarters in Fort Worth, Texas.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

27 Patents

#36 in Fort Worth, TX

#710 in Texas

#12,428 in US

#24,034 in the World

Fort Worth, TX, United States of America

Galderma Laboratories Inc.

Forward Citations = 245

21 inventors:

Jack A DeJovin (12 out of 12 patents)

Isabelle Jean DeJovin (10 out of 10 patents)

Robert A Ashley (7 out of 17 patents)

4. Michael Graeber (6 out of 30 patents)

5. Philip Freidenreich (6 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Galderma Laboratories Inc.. Retrieved from https://idiyas.com/company/galderma-laboratories

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…